European Commission following REACH
This article was originally published in The Rose Sheet
Executive Summary
Commissioner for Industry and Entrepreneurship Antonio Tajani and Environment Commissioner Janez Potocnik visited the European Chemicals Agency March 25 and met with stakeholders in advance of Nov. 30 REACH deadline for registration of chemicals manufactured or imported in volumes equal to or greater than 1,000 tons annually, as well as CMR substances, or those identified as potentially carcinogenic, mutagenic or reprotoxic. Chemicals management is of "very high concern," and finding solutions to practical problems - particularly issues that make the process difficult for small and medium enterprises - is a priority, EC leaders indicate. A Directors Contact Group has been devised to monitor industry's progress. "REACH ensures a high level of protection of human health and the environment while also playing an important role to encourage innovation, foster competitiveness and better enable enterprises [to] meet essential demands of consumers," states Tajani. Geert Dancet, executive director of ECHA, says EC chiefs' active involvement "signals that the Commission and ECHA stand side-by-side in making REACH work." ECHA and EC have agreed to expand "candidate list" for substances of very high concern from 29 to 106 substances by 2012. The agency's first progress report includes recommendations for the improvement of registration dossiers (1"The Rose Sheet" March 29, 2010)
You may also be interested in...
ECHA Offers REACH Progress Report, Urging Registrants To Improve Dossiers
By the end of 2009, the European Chemicals Agency had completed 15 of 30 "compliance checks" initiated since registration dossiers started dribbling in under REACH, and almost half of its checks have inspired quality observation letters due to inadequacies, the agency says
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.